Evidence map›Paper›PMID 33597848›Full record

ArticleFrontiers in molecular neuroscience2021

PGC-1α Signaling Increases GABA(A) Receptor Subunit α2 Expression, GABAergic Neurotransmission and Anxiety-Like Behavior in Mice.

Taavi Vanaveski, Svetlana Molchanova, Dan Duc Pham, Annika Schäfer, Ceren Pajanoja, Jane Narvik, Vignesh Srinivasan, Mari Urb, Maria Koivisto, Eero Vasar and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Taavi VanaveskiMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Svetlana MolchanovaMolecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
Dan Duc PhamMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Annika SchäferMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Ceren PajanojaMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Jane NarvikInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Vignesh SrinivasanMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Mari UrbProtobios LCC, Tallinn, Estonia.
Maria KoivistoMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Eero VasarInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Tönis TimmuskProtobios LCC, Tallinn, Estonia.
Rimante MinkevicieneMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Ove ErikssonMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Maciej LalowskiMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
Tomi TairaDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine and Neuroscience Center, HiLIFE, University of Helsinki, Helsinki, Finland.
Laura KorhonenDepartment of Child and Adolescent Psychiatry and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Vootele VoikarNeuroscience Center and Laboratory Animal Center, HiLIFE, University of Helsinki, Helsinki, Finland.
Dan LindholmMedicum, Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIMinerva Foundation · FIProtobios (Estonia) · EEUniversity of Tartu · EEInstitute of Bioorganic Chemistry, Polish Academy of Sciences · PLLinköping University · SEQuretec (Estonia) · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a master regulator of mitochondria biogenesis and cell stress playing a role in metabolic and degenerative diseases. In the brain PGC-1α expression has been localized mainly to GABAergic interneurons but its overall role is not fully understood. We observed here that the protein levels of γ-aminobutyric acid (GABA) type A receptor-α2 subunit (GABARα2) were increased in hippocampus and brain cortex in transgenic (Tg) mice overexpressing PGC-1α in neurons. Along with this, GABARα2 expression was enhanced in the hippocampus of the PGC-1α Tg mice, as shown by quantitative PCR. Double immunostaining revealed that GABARα2 co-localized with the synaptic protein gephyrin in higher amounts in the striatum radiatum layer of the hippocampal CA1 region in the Tg compared with Wt mice. Electrophysiology revealed that the frequency of spontaneous and miniature inhibitory postsynaptic currents (mIPSCs) was increased in the CA1 region in the Tg mice, indicative of an augmented GABAergic transmission. Behavioral tests revealed an increase for anxiety-like behavior in the PGC-1α Tg mice compared with controls. To study whether drugs acting on PPARγ can affect GABARα2, we employed pioglitazone that elevated GABARα2 expression in primary cultured neurons. Similar results were obtained using the specific PPARγ agonist, N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino) ethyl]-L-tyrosine hydrate (GW1929). These results demonstrate that PGC-1α regulates GABARα2 subunits and GABAergic neurotransmission in the hippocampus with behavioral consequences. This indicates further that drugs like pioglitazone, widely used in the treatment of type 2 diabetes, can influence GABARα2 expression via the PPARγ/PGC-1α system.

Indexed as

anxietybehavioral testGABA-A receptorsgene expressionneurotransmissionPGC-1αpioglitazonePPARγ

Identifiers

PMID33597848
PMCPMC7882546
OpenAlexW3128509986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.